Latest Breaking News On - Matts johansen - Page 9 : comparemela.com

Aker Biomarine targets $200m EBITDA by 2024 - Undercurrent News

Kjell Inge Rokke's Aker Biomarine appoints SVP to lead the group's entry into pharmaceuticals

He will develop and drive growth outside of the company’s core supplement segment, with a focus on pharmaceutical and medical food applications.

Aker BioMarine appoints Douglas C. Hicks as Senior Vice President, Business Development & Strategy

Share this article Share this article LYSAKER, Norway, May 27, 2021 /PRNewswire/ Aker BioMarine, the global biotech innovator and world-leading supplier of krill, announces the appointment of biotechnology and pharmaceutical executive Douglas C. Hicks to the position of Senior Vice President – Business Development and Strategy, to lead Aker BioMarine s entry into the pharmaceutical segment. Aker BioMarine appoints Douglas C. Hicks as Senior Vice President, Business Development & Strategy. Based out of the U.S., Mr. Hicks will play an integral role in the development of new product segments for Aker BioMarine s LYSOVETA™, a new krill-based LPC-EPA/DHA delivery platform. He will develop and drive LYSOVETA s growth outside of the company s core supplement segment, with a focus on pharmaceutical and medical food applications.

Aker BioMarine appoints Douglas C. Hicks as Senior Vice President, Business Development & Strategy

Aker BioMarine Lists On Oslo Børs

<p><span>Euronext today congratulates Aker BioMarine on its transfer from Euronext Growth to Oslo B&oslash;rs (ticker code: AKBM).</span></p>